|
Otto Skolling Chairman |
M.Sc. in Chemistry, Investment Manager at Karolinska Development AB, has 20 years of broad-based pharmaceutical and med tech. industry experience, including product development, business development and project management gained through management positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. |
|
Conny Bogentoft |
PhD in Medicinal Chemistry, Associate Professor in Pharmaceutical Chemistry, today CEO at Karolinska Development AB. Conny Bogentoft has with more than 30 years' experience of pharmaceutical industry, as senior R&D management positions and as a member of board of directors of Galenica AB, demonstrated his ability to successfully plan, implement and develop clinical and business strategies. Previous appointments include Vice President of Astra Arcus, President of Kabi Invent, Research Director at ACO Läkemedel, and Chairman of the Swedish Academy of Pharmaceutical Sciences. |
|
Mingde Wang |
MD, PhD, is one of the founders of Umecrine AB. He has a degree from Nanjing University School of Medicine, China, and has a certification to practice medicine in Sweden. He is a MD of Neuroscience at Umeå University, Associate professor in Obstetrics and gynecology and did post-doc in Neuroscience at Washington University, School of Medicine, St. Louis, USA. Mingde Wang has a position as Assistant Professor at the Department of Clinical Science, Obstetrics and Gynecology and a part-time research internship at the Women's Clinic, Norrlands University Hospital, Umeå. |
|
Torbjörn Bäckström |
MD, PhD, co-founder and CEO of Umecrine AB, also serves as Chief Scientific Officer and Medical Director in Umecrine Mood and Umecrine Cognition. Torbjörn Bäckström is currently part time professor at the Department of Clinical Science, Obstetrics and Gynecology, Umeå University. He is also manager of the Umeå Neurosteroid Research Center. Torbjörn Bäckström's main focus of research since 1972 is the effect of sex and stress hormones on the brain and conditions induced by these hormones, he has more than 400 scientific publications within this area and he is a frequently invited key-note speaker at scientific congresses around the world. In 1989 to 1995 Torbjörn Bäckström served at the scientific board of the company, CoCensys Inc., Irvine CA, USA, based on his own research and the research of Professor Kelvin Gee, University of California. Several active substances were developed and one of those is currently in phase III of clinical assessment. CoCensys, with approximately 120 employees, was listed on the NASDAQ stock market until 1998, when it was sold to a larger pharmaceutical company. |
|
Per-Olof Gunnesson |
Business School degree, has more than 30 years experience in biotech/pharmaceutical industry, including the ASTRA group. |